A

Advanced ENT and Allergy | Breckenridge

Research site

(Unclaimed)

Location

2944 Breckenridge Lane, Louisville, Kentucky, United States of America

Site insights

Top conditions

Top treatments

OTO-313

Dupilumab

Mometasone furoate

OTO-413

Omalizumab

CDX-0159

Fluticasone Propionate

Verekitug

Aroxybutynin

AD109

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 28 total trials

Locations recently updated

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (CEREN-2)

EFC18419 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the...

Enrolling

Chronic Rhinosinusitis With Nasal Polyps

Drug: Mometasone furoate nasal spray (MFNS)

Drug: Itepekimab (SAR440340)

A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)

The purpose of this Phase 3, randomized, double-blind, placebo-controlled study is to assess the activity and safety of barzolvolimab compared to pla...

Enrolling

Cold-Induced Urticaria

Chronic Inducible Urticaria

Drug: Barzolvolimab

Drug: Matching Placebo

Continuation Protocol for Obstructive Sleep Apnea (OSA)

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only

OSA

Drug: Aroxybutynin and Atomoxetine

Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma

Arm 1 ( Phase 2/3 Run in ):PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary O...

Enrolling

Oral Squamous Cell Carcinoma

Drug: PRV111 (Cisplatin Transmucosal System)

Drug: PRV211 (Intraoperative Cisplatin System)